埃克替尼联合全脑放疗治疗老年肺腺癌脑转移疗效观察(1)
【摘要】 目的 分析埃克替尼联合全脑放疗治疗老年肺腺癌脑转移的疗效及不良反应。方法 57例肺腺癌脑转移患者， 均为不能耐受化疗或不愿接受化疗的老年患者， 根据治疗方法的不同分为靶向联合放疗组(27例)及单纯放疗组(30例)。观察并比较两组治疗有效率、中位生存时间、不良反应。结果 靶向联合放疗组与单纯放疗组患者有效率(81.5% VS 40.0%)及疾病控制率(96.3% VS 73.3%)比较， 差异均有统计学意义(P<0.05)；靶向联合放疗组中位生存时间11个月， 1年生存率51.9%；单纯放疗组中位生存时间7个月， 1年生存率23.3%。两组1年生存率比较， 差异有统计学意义(P=0.02<0.05)。靶向联合放疗组主要不良反应为皮疹， 皮疹发生率为63.0%， 有2例患者皮疹达4级， 经对症处理， 能耐受继续口服靶向药物。结论 埃克替尼联合放疗治疗老年肺腺癌脑转移疗效好， 不良反应少， 值得临床推广应用。
【关键词】 埃克替尼；脑转移；肺癌
DOI：10.14163/j.cnki.11-5547/r.2015.27.002
, 百拇医药
Icotinib combined with whole brain radiotherapy in the treatment of senile lung adenocarcinoma with brain metastases WANG Zong-zhan， ZHOU Mi， TIAN Ying-ying， et al. The First Department of Radiotherapy， Qingdao City Tumor Hospital， Qingdao 266042， China
【Abstract】 Objective To analyze curative effect and adverse reactions of icotinib combined with whole brain radiotherapy in the treatment of senile lung adenocarcinoma with brain metastases patients. Methods A total of 57 senile lung adenocarcinoma with brain metastases patients， without receiving chemotherapy， were divided by different treatment methods into targeted combined radiotherapy group (27 cases) and single radiotherapy group (30 cases). Effective rate， median survival time， survivorship curve， and adverse reactions of the two groups were observed and compared. Results There were statistically significant differences of effective rate (81.5% VS 40.0%) and disease control rate (96.3% VS 73.3%) between the targeted combined radiotherapy group and the single radiotherapy group (P<0.05). The targeted combined radiotherapy group had median survival time as 11 months and 1 year survival rate as 51.9%， and those in the single radiotherapy group were 7 months and 23.3%. The difference of 1 year survival rate between the two groups had statistical significance (P=0.02<0.05). Main adverse reactions in the targeted combined radiotherapy group was rash， with the occurrence rate as 63.0%. There were 2 cases with grade 4 rash， and they received continuous targeted drug by oral administration after symptomatic treatment. Conclusion Implement of icotinib combined with radiotherapy provides good curative effect and few adverse reactions in treating senile lung adenocarcinoma with brain metastases patients. It is worth clinical promotion and application.
【Key words】 Icotinib； Brain metastases； Lung cancer
恶性肿瘤发生脑转移以肺癌最为多见， 占50%～60%[1]。初诊时患者有16.5%～19.9%伴有脑转移， 肺腺癌发生率高达43.3%[2]。目前全脑放疗仍为脑转移瘤的标准治疗方案， 但大部分患者的中位生存期仅延长4～6个月。埃克替尼是我国自主研发的口服表皮生长因子受体酪氨酸激酶抑制剂， 对晚期非小细胞肺癌患者有一定的抗肿瘤作用。本文回顾性分析并比较靶向联合放疗组的27例肺腺癌脑转移患者及单纯放疗组的30例肺腺癌脑转移患者的临床治疗效果， 所有患者不能耐受化疗或不愿接受化疗， 现报告如下。, http://www.100md.com(王宗站 周宓 田莹莹 邢晓波)
【关键词】 埃克替尼；脑转移；肺癌
DOI：10.14163/j.cnki.11-5547/r.2015.27.002
, 百拇医药
Icotinib combined with whole brain radiotherapy in the treatment of senile lung adenocarcinoma with brain metastases WANG Zong-zhan， ZHOU Mi， TIAN Ying-ying， et al. The First Department of Radiotherapy， Qingdao City Tumor Hospital， Qingdao 266042， China
【Abstract】 Objective To analyze curative effect and adverse reactions of icotinib combined with whole brain radiotherapy in the treatment of senile lung adenocarcinoma with brain metastases patients. Methods A total of 57 senile lung adenocarcinoma with brain metastases patients， without receiving chemotherapy， were divided by different treatment methods into targeted combined radiotherapy group (27 cases) and single radiotherapy group (30 cases). Effective rate， median survival time， survivorship curve， and adverse reactions of the two groups were observed and compared. Results There were statistically significant differences of effective rate (81.5% VS 40.0%) and disease control rate (96.3% VS 73.3%) between the targeted combined radiotherapy group and the single radiotherapy group (P<0.05). The targeted combined radiotherapy group had median survival time as 11 months and 1 year survival rate as 51.9%， and those in the single radiotherapy group were 7 months and 23.3%. The difference of 1 year survival rate between the two groups had statistical significance (P=0.02<0.05). Main adverse reactions in the targeted combined radiotherapy group was rash， with the occurrence rate as 63.0%. There were 2 cases with grade 4 rash， and they received continuous targeted drug by oral administration after symptomatic treatment. Conclusion Implement of icotinib combined with radiotherapy provides good curative effect and few adverse reactions in treating senile lung adenocarcinoma with brain metastases patients. It is worth clinical promotion and application.
【Key words】 Icotinib； Brain metastases； Lung cancer
恶性肿瘤发生脑转移以肺癌最为多见， 占50%～60%[1]。初诊时患者有16.5%～19.9%伴有脑转移， 肺腺癌发生率高达43.3%[2]。目前全脑放疗仍为脑转移瘤的标准治疗方案， 但大部分患者的中位生存期仅延长4～6个月。埃克替尼是我国自主研发的口服表皮生长因子受体酪氨酸激酶抑制剂， 对晚期非小细胞肺癌患者有一定的抗肿瘤作用。本文回顾性分析并比较靶向联合放疗组的27例肺腺癌脑转移患者及单纯放疗组的30例肺腺癌脑转移患者的临床治疗效果， 所有患者不能耐受化疗或不愿接受化疗， 现报告如下。, http://www.100md.com(王宗站 周宓 田莹莹 邢晓波)